Sánchez Montero, JoséSánchez Montero, JoséGonzález Matilla, Juan FranciscoAlcántara León, Andrés RafaelDoadrio Villarejo, Antonio Luis2024-01-112024-01-112019-06-05González Juan F, Alcántara Andrés R., Doadrio Antonio L., Sánchez-Montero Jose María. Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches, Expert Opinion on Drug Discovery, 2019 Jun 14:9, 879-911746-044110.1080/17460441.2019.1623201https://hdl.handle.net/20.500.14352/92533Este trabajo fue realizado por invitación expresa de la editorial Taylor and Francis sin coste alguno para los autoresIntroduction: Alzheimer’s disease (AD), the most common type of dementia among older adults, is a chronic neurodegenerative pathology that causes a progressive loss of cognitive functioning with a decline of rational skills. It is well known that AD is multifactorial, so there are many different pharmacological targets that can be pursued. Areas covered: The authors highlight the strategic value of privileged scaffolds in a multi-target lead compound generation against AD, exploring the concept of multi-target design, with a special emphasis on hybrid compounds. Hence, the most promising building blocks for designing and synthesizing hybrid anti-AD drugs are shown, while also presenting the more advanced hybrid compounds. Expert opinion: The available therapeutic arsenal for AD, designed under the traditional paradigm of ‘one-drug/one target/one-disease’, is based on the inhibition of brain acetylcholinesterase (AChE) to increase acetylcholine (ACh) levels. However, this classical approach has not been sufficiently effective when used to treat any multifactor-depending pathology (cancer, diabetes or AD). The multi-target drug concept has been quickly adopted by medicinal chemists. The basic research developments reported in recent years are a solid foundation that will pave the way for the construction of future AD therapeutics.engjournal article1746-045Xhttps://doi.org/10.1080/17460441.2019.1623201restricted access6616.894-053.9Alzheimer’s diseasecurrent hypothesesmulti-target direct ligandprivileged building blocksCiencias BiomédicasCiencias24 Ciencias de la Vida23 Química